Alk­er­mes sub­mits long await­ed NDA for schiz­o­phre­nia, bipo­lar drug; Is a uni­corn bub­ble drag­ging the IPO mar­ket?

→ The Alk­er­mes $ALKS team — who back in Ju­ly laid out their plans to add bipo­lar I dis­or­der to their list of con­di­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.